Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 378

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Open access
Ricciuti, Biagio, Wang, Xinan, Alessi, Joao V., Rizvi, Hira, Mahadevan, Navin R., Li, Yvonne Y., Polio, Andrew, Lindsay, James, Umeton, Renato, Sinha, Rileen, Vokes, Natalie I., Recondo, Gonzalo, Lamberti, Giuseppe, Lawrence, Marissa, Vaz, Victor R., Leonardi, Giulia C., Plodkowski, Andrew J., Gupta, Hersh, Cherniack, Andrew D., Tolstorukov, Michael Y., Sharma, Bijaya, Felt, Kristen D., Gainor, Justin F., Ravi, Arvind, Getz, Gad, Schalper, Kurt A., Henick, Brian, Forde, Patrick, Anagnostou, Valsamo, Jänne, Pasi A., Van Allen, Eliezer M., Nishino, Mizuki, Sholl, Lynette M., Christiani, David C., Lin, Xihong, Rodig, Scott J., Hellmann, Matthew D., Awad, Mark M. · 2022 · JAMA Oncology

Abstract

Importance: Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about the optimal TMB threshold that best discriminates improved outcomes of immune checkpoint inhibitor therapy among patients with non–small cell lung cancer (NSCLC). Objectives: To determine the association between increasing TMB levels and immunotherapy efficacy across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with NSCLC. Design, Setting, and Participants: This multicenter cohort study included patients with advanced NSCLC treated with immunotherapy who received programmed cell death–1 (PD-1) or PD-L1 inhibition in the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center (MSKCC), and in the Stand Up To Cancer (SU2C)/Mark Foundation data sets. Clinicopathological and genomic data were collected from patients between September 2013 and September 2020. Data analysis was performed from November 2021 to February 2022. Exposures: Treatment with PD-1/PD-L1 inhibition without chemotherapy. Main Outcomes and Measures: Association of TMB levels with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: In the entire cohort of 1552 patients with advanced NSCLC who received PD-1/PD-L1 blockade, the median (range) age was 66 (22-92) years, 830 (53.5%) were women, and 1347 (86.8%) had cancer with nonsquamous histologic profile. A regression tree modeling ORR as a function of TMB identified 2 TMB groupings in the discovery cohort (MSKCC), defined as low TMB (≤19.0 mutations per megabase) and high TMB (>19.0 mutations per megabase), which were associated with increasing improvements in ORR, PFS, and OS in the discovery cohort and in 2 independent cohorts (DFCI and SU2C/Mark Foundation). These TMB levels also were associated with significant improvements in outcomes of immunotherapy in each PD-L1 tumor proportion score subgroup of less than 1%, 1% to 49%, and 50% or higher. The ORR to PD-1/PD-L1 inhibition was as high as 57% in patients with high TMB and PD-L1 expression 50% or higher and as low as 8.7% in patients with low TMB and PD-L1 expression less than 1%. Multiplexed immunofluorescence and transcriptomic profiling revealed that high TMB levels were associated with increased CD8-positive, PD-L1–positive T-cell infiltration, increased PD-L1 expression on tumor and immune cells, and upregulation of innate and adaptive immune response signatures. Conclusions and Relevance: These findings suggest that increasing TMB levels are associated with immune cell infiltration and an inflammatory T-cell–mediated response, resulting in increased sensitivity to PD-1/PD-L1 blockade in NSCLC across PD-L1 expression subgroups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2022.1981

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 378

Metadata

Authors
Ricciuti, B., Wang, X., Alessi, J. V., Rizvi, H., Mahadevan, N. R., Li, Y. Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N. I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V. R., Leonardi, G. C., Plodkowski, A. J., Gupta, H., Cherniack, A. D., Tolstorukov, M. Y., Sharma, B., Felt, K. D., Gainor, J. F., Ravi, A., Getz, G., Schalper, K. A., Henick, B., Forde, P., Anagnostou, V., Jänne, P. A., Van Allen, E. M., Nishino, M., Sholl, L. M., Christiani, D. C., Lin, X., Rodig, S. J., Hellmann, M. D., & Awad, M. M.
Venue
JAMA Oncology
Published
2022-08-01
Volume
8
Issue
8
Pages
1160
ISSN
2374-2437 (ISSN-L)
OpenAlex
W4283030292
Cited by
378
References
28
FWCI
29.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. https://app.cochat.ai/papers/10.1001/jamaoncol.2022.1981
The paper
Ricciuti, B., Wang, X., Alessi, J. V., Rizvi, H., Mahadevan, N. R., Li, Y. Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N. I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V. R., Leonardi, G. C., Plodkowski, A. J., Gupta, H., Cherniack, A. D., . . . Awad, M. M. (2022). Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2022.1981

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.